Philip Morris International Announces Appointment of Two Former U.S. FDA Officials, Highlighting the Company’s Continued Commitment to Smoke-Free Product Science and Regulation
14 September 2022 - 1:00PM
Business Wire
- Dr. Badrul Chowdhury Appointed Chief Life Sciences Officer
- Dr. Matthew Holman Appointed Vice President, U.S. Scientific
Engagement and Regulatory Strategy
Philip Morris International Inc. (PMI) (NYSE: PM) announced
today that it has appointed two former United States Food and Drug
Administration (U.S. FDA) officials to key positions to accelerate
its science-based transformation.
Dr. Badrul Chowdhury is appointed PMI’s Chief Life Sciences
Officer, Smoke-Free Products, succeeding Jorge Insuasty, who will
complete his move into the recently created position of President,
Vectura Fertin Pharma. After a short transition period, Badrul will
join PMI’s Senior Management Team in January 2023, reporting to
Jacek Olczak, Chief Executive Officer.
“I am delighted to welcome Badrul to PMI and look forward to
working closely with him as he leads our talented team of
scientific experts,” said Jacek Olczak. “He is an accomplished
scientist and regulatory strategist, with decades of leadership
experience, both in industry and as a regulator within the U.S.
FDA’s Pulmonary Division. His wealth of knowledge and experience
will be critical to help achieve our ambition of a smoke-free
future. I also extend my sincere thanks to Jorge Insuasty for his
contributions to the function as he moves to oversee Vectura Fertin
Pharma full-time.”
Dr. Chowdhury joins PMI from a U.S.-based biotech company
developing inhalation products for rare respiratory diseases, where
he was Chief Medical Officer. Prior to that, he was AstraZeneca’s
Senior Vice President and Chief Physician-Scientist for Respiratory
Inflammation and Autoimmunity Late-Stage Development in
Biopharmaceuticals R&D. Before joining the pharmaceutical
industry, Dr. Chowdhury served as Director, Division of Pulmonary,
Allergy, and Rheumatology Products, Center for Drug Evaluation and
Research (CDER) at the U.S. FDA for almost 21 years, from 1997 to
2018, providing scientific and regulatory oversight of therapies
for lung, autoimmune, and inflammatory diseases. Dr. Chowdhury is a
medical doctor and holds a PhD in immunology.
“Joining the PMI team is an exciting new adventure,” said Dr.
Chowdhury. “The investment the company has already made in
delivering high-quality science to support its transformation and
smoke-free vision is unprecedented. I am thrilled to have the
chance to help move the company forward faster and to truly seize
the public health opportunity that well-regulated smoke-free
products present. I look forward to working with the Senior
Management Team and the entire Life Sciences function to accelerate
progress.”
Dr. Matthew (“Matt”) Holman is appointed as PMI’s Vice President
of U.S. Scientific Engagement and Regulatory Strategy, reporting to
Deepak Mishra, President of PMI Americas.
“We are delighted that Matt will be joining PMI to further
accelerate our journey toward a smoke-free future, particularly
here in the United States,” said Deepak Mishra. “As we transform,
we recognize the importance of bringing together diverse
perspectives, including those of regulatory bodies and the
scientific community. Matt’s solid scientific and stakeholder
knowledge, combined with his passion for tobacco harm reduction,
will be invaluable.”
Dr. Holman joins PMI from the U.S. FDA, where he served for more
than 20 years, most recently as Director of the Office of Science
at the Center for Tobacco Products (CTP). At CTP, Holman was
instrumental in building the FDA’s marketing application review
programs. He served as CTP’s chief scientist, playing a significant
role in guiding policy decisions, developing rulemaking and
guidance documents, and overseeing a robust regulatory science
research program for tobacco products. Previously, Holman worked at
the FDA’s CDER on over-the-counter drug products, including as
Deputy Director of the Division of Nonprescription Regulation
Development. He received his PhD in biochemistry from the
University of Maryland at College Park.
“Having spent more than two decades working to improve public
health as a regulator, I am delighted to join forces with PMI, a
company that is firmly committed to the goal of accelerating the
end of smoking,” said Dr. Holman. “PMI is leading the industry in a
major transformation that can ultimately provide an unprecedented
breakthrough for public health. I’m excited to make this move and
join PMI on its smoke-free journey.”
The appointment of these seasoned scientific and regulatory
experts complements the recent hiring of Keagan Lenihan, who joined
PMI in May 2022 as Vice President of Government Affairs and Public
Policy, and Head of its D.C. office. Lenihan spent two decades
working in government, corporate, and public policy, including as
Associate Commissioner for External Affairs and Strategic
Initiatives and then Chief of Staff at the U.S. FDA.
Philip Morris International: Delivering a Smoke-Free
Future
Philip Morris International (PMI) is a leading international
tobacco company working to deliver a smoke-free future and evolving
its portfolio for the long term to include products outside of the
tobacco and nicotine sector. The company’s current product
portfolio primarily consists of cigarettes and smoke-free products,
including heat-not-burn, vapor, and oral nicotine products, which
are sold in markets outside the U.S. Since 2008, PMI has invested
more than USD 9 billion to develop, scientifically substantiate,
and commercialize innovative smoke-free products for adults who
would otherwise continue to smoke, with the goal of completely
ending the sale of cigarettes. This includes the building of
world-class scientific assessment capabilities, notably in the
areas of pre-clinical systems toxicology, clinical and behavioral
research, as well as post-market studies. The U.S. Food and Drug
Administration (FDA) has authorized the marketing of versions of
PMI’s IQOS Platform 1 devices and consumables as Modified Risk
Tobacco Products (MRTPs), finding that exposure modification orders
for these products are appropriate to promote the public health. As
of June 30, 2022, excluding Russia and Ukraine, PMI’s smoke-free
products were available for sale in 70 markets, and PMI estimates
that approximately 13.2 million adults around the world had already
switched to IQOS and stopped smoking. With a strong foundation and
significant expertise in life sciences, in February 2021 PMI
announced its ambition to expand into wellness and healthcare areas
and deliver innovative products and solutions that aim to address
unmet consumer and patient needs. For more information, please
visit www.pmi.com and www.pmiscience.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220914005023/en/
David Fraser Philip Morris International T. +41 (0)58 242 4500
E. david.fraser@pmi.com
Philip Morris (NYSE:PM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Philip Morris (NYSE:PM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024